|

LY3537982 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Olomorasib

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Eli Lilly and Company2

Indications

  • Carcinoma, Non-Small-Cell Lung2
  • Lung Cancer2
  • Cancer2
  • Biliary Tract Neoplasms1
  • Ovarian Neoplasms1

Birmingham, Alabama1 trial

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

University of Alabama at Birmingham

Phase 1/2

Huntsville, Alabama1 trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.